Response of Topical Capsaicin in Alopecia Areata

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

1997-08-31

Study Completion Date

2000-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has been postulated that Alopecia Areata (AA) is, at least in part, a neurologically mediated disease. Research supporting this theory includes the finding that nerves surrounding the hair follicles are collapsed. We want to take this research a step further and show that not only are these perifollicular nerves collapsed, but that their function is also impaired.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice

NCT00177099

Alopecia

COMPLETED PHASE1

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

NCT03346668

Scarring Alopecia Frontal Fibrosing Alopecia Lichen Planopilaris +2 more

COMPLETED EARLY_PHASE1

Alefacept in Patients With Severe Scalp Alopecia Areata

NCT00167102

Alopecia Areata

COMPLETED NA

Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss

NCT02150187

Androgenetic Alopecia

COMPLETED PHASE2

Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin

NCT00408798

Alopecia Areata

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the function of perifollicular scalp nerves in AA we will look at the response of these nerves to the topical medication capsaicin. Under normal circumstances topical capsaicin is known to target nerves in the peripheral nervous system causing short-term release of the neuropeptide Substance P (SP) as well as long-term transient depletion of SP. We expect the AA patients will respond abnormally to topical capsaicin treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alopecia Areata

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Capsaicin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have alopecia totalis or universalis.
* Be in good health.
* Not be taking any medications including topical medications
* Be 18 years or older.
* Be willing to apply study medication or vehicle as directed, comply with instructions and commit to follow-up visits.
* Not have had hair chemically treated (including colored hair, permed hair, etc) within the month prior to the study.

Exclusion Criteria

* Absence of extensive alopecia areata.
* People not in good health.
* People taking medications.
* Allergies to capsaicin.
* Presence of irritated or visibly inflamed scalp.
* Having had hair chemically treated (including colored hair, permed hair, etc.) within the month prior to study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes